Key result
Concomitant use of proton pump inhibitors and clopidogrel after stent implantation was associated with an increased risk of major adverse cardiovascular and cerebrovascular events compared to clopidogrel alone.
Why the study?
PPIs reduce clopidogrel response yet are needed during long-term DAPT, and ethnic variance may influence this response and clinical outcomes.
Does concomitant use of proton pump inhibitors and clopidogrel increase major adverse cardiovascular and cerebrovascular events in patients after stent implantation, and does ethnic variance affect this outcome?
Meta-Analysis (n=79,670)
Does concomitant use of proton pump inhibitors and clopidogrel increase major adverse cardiovascular and cerebrovascular events in patients after stent implantation, and does ethnic variance affect this outcome?
Concomitant use of PPIs and clopidogrel after stent implantation is associated with increased adverse cardiovascular outcomes overall, but this risk may be attenuated in Asian populations, suggesting ethnic variance in drug metabolism.
Answers are grounded in this paper and cite their sources.
May warrant PPI alternatives with clopidogrel post-stenting; extends evidence by suggesting attenuated risk in Asian populations.
BACKGROUND: Pharmacokinetic and pharmacodynamic study showed a lower clopidogrel response when coprescribed with proton pump inhibitors (PPIs). Despite this, PPIs is necessary for patients treated with long term dual antiplatelet therapy (DAPT). Ethnic variance also played a different effect on clopidogrel response. Our study evaluated the effect of concomitant use of DAPT and PPIs and assessed whether ethnic variance exert different effect on clinical outcomes. METHODS: We carefully searched EMBASE, PubMed/Medline databases, and the Cochrane library in April 2019. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE) and individual endpoints reported. We also focused on bleeding events. Studies were excluded if the follow-up were <12 months and patients were not treated with clopidogrel after stent implantation. RESULTS: A total of 18 studies were included in the systematic review (involving 79,670 patients). No randomized controlled trials (RCTs) were included. PPIs comedication were associated with increased MACCE (odds ratio [OR] = 1.38; 95% confidence interval [CI] = 1.28-1.49) while not associated with decreased bleeding risks, such as gastrointestinal bleeding (OR = 1.05; 95% CI = 0.53-2.11). PPIs comedication were associated with increased risk for all endpoints among Caucasian population while not with increased risk for MACE (OR = 1.20; 95% CI = 0.99-1.39), all-cause death (OR = 1.24; 95% CI = 0.74-2.06), cardiac-death (OR = 1.29; 95% CI = 0.64-2.57) among Asian population. CONCLUSION: PPIs comedication were associated with adverse clinical outcomes, and ethnic variance may exert different effect on clinical outcomes. Subgroup analysis indicated that concomitant use of PPI might be suitable for Asian patients after stent implantation.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2021) conducted a meta-analysis in Stent implantation requiring clopidogrel therapy (n=79,670). Concomitant use of proton pump inhibitors (PPIs) and clopidogrel vs. Clopidogrel alone was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE) (OR 1.38, 95% CI 1.28-1.49). Concomitant use of proton pump inhibitors and clopidogrel after stent implantation was associated with an increased risk of major adverse cardiovascular and cerebrovascular events compared to clopidogrel alone.
Synapse has enriched 10 related papers. Consider them for comparative context: